Depression is often viewed through the lens of brain chemistry, with neurotransmitters such as serotonin, dopamine, and norepinephrine receiving much of the attention. Although these chemical messengers play important roles in mood regulation, researchers now recognize that depression is far more complex than a simple neurotransmitter imbalance [1].
One important development in mental health research is the growing evidence that immune activity, particularly persistent inflammatory signaling, may contribute to the development or persistence of depressive symptoms in some people [2].
The idea that inflammation can affect mental health may seem surprising. Inflammation is more commonly associated with infections, injuries, or swollen joints. However, the immune system communicates extensively with the brain, and persistent low-grade inflammation may influence how people think, feel, and behave. Understanding this relationship could support more personalized approaches to depression, especially for people with inflammatory conditions. It is important, however, to distinguish an association from a universal cause: inflammation is only one potential contributor to a complex and heterogeneous condition.
What Is Inflammation?
Inflammation is part of the body's natural defense against injury, infection, and other harmful stimuli. During an acute inflammatory response, immune cells release signaling molecules, including cytokines, that help coordinate healing and defend against pathogens.
In the short term, inflammation is essential. It helps fight infections, repair wounds, and restore damaged tissue. Problems can arise when inflammatory signaling fails to resolve and remains active over longer periods.
Chronic, low-grade inflammation is associated with numerous conditions, including cardiovascular disease, type 2 diabetes, obesity, some autoimmune and neurodegenerative diseases, and depression [3]. Unlike acute inflammation, it may produce few obvious symptoms while affecting multiple organ systems, including the brain.
What Are Cytokines?
Cytokines are small signaling proteins that help immune cells communicate with one another and with other tissues. Some cytokines tend to promote inflammation, whereas others help regulate or resolve it. A healthy immune response depends on the timing and balance of these signals.
Several inflammatory markers have been studied in depression, including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interferon-gamma (IFN-γ), and C-reactive protein (CRP). On average, some of these markers are elevated in groups of people with major depressive disorder compared with healthy control groups [4,5]. The findings vary by marker, sample type, medication status, and study population, and many individuals with depression do not show an inflammatory profile.
How Can Inflammation Affect the Brain?
The brain is partly protected by the blood-brain barrier, but it is not isolated from the immune system. Immune-to-brain communication can occur through circulating signals, neural pathways, transport mechanisms at the blood-brain barrier, and cells associated with the brain's blood vessels and immune system [2].
Altering Neurotransmitter Metabolism
Inflammatory signaling can affect the synthesis, release, and reuptake of neurotransmitters such as serotonin, dopamine, and norepinephrine.
One proposed mechanism involves indoleamine 2,3-dioxygenase (IDO), an enzyme that shifts tryptophan metabolism toward the kynurenine pathway. Under inflammatory conditions, this pathway may reduce the amount of tryptophan available for serotonin synthesis while changing the balance of neuroactive kynurenine metabolites [2].
These metabolites do not all act in the same way. Some may be neuroprotective, whereas others, including quinolinic acid, can stimulate N-methyl-D-aspartate (NMDA) glutamate receptors and may contribute to oxidative stress and neuronal dysfunction when present in excess.
Disrupting Glutamate Regulation
Inflammatory signaling may also alter glutamate release and clearance. Excess extracellular glutamate can disrupt synaptic signaling and, in severe or prolonged circumstances, contribute to excitotoxic stress [2]. Glutamate dysregulation is one area of investigation in depression and is relevant to the rapid antidepressant effects of glutamate-modulating treatments such as ketamine. This does not mean, however, that inflammation alone explains why ketamine works.
Changing Microglial Activity
Microglia are immune cells within the central nervous system. They help monitor the brain's environment, clear cellular debris, remodel synapses, and respond to injury or infection. Persistent immune signaling may shift microglial function in ways that promote neuroinflammation and alter communication between neurons. The biology is more nuanced than microglia being simply “on” or “off,” and much of the mechanistic evidence comes from preclinical studies [2].
Reducing Neuroplasticity
The brain continually adapts by strengthening, weakening, and forming neural connections. Brain-derived neurotrophic factor (BDNF) supports several processes involved in synaptic plasticity, learning, and memory [6]. Inflammatory signaling may interfere with BDNF-related pathways and neuroplasticity. Studies have also found lower peripheral BDNF levels, on average, in people with major depressive disorder, although a blood measurement does not directly reveal BDNF activity inside the brain [6].
Clinical Evidence Linking Inflammation and Depression
Meta-analyses have reported higher average levels of CRP, IL-6, TNF-α, and several other inflammatory markers in people with major depressive disorder [5,7]. These are group-level findings with substantial variation between individuals and studies; they are not evidence that every person with depression has chronic inflammation.
Some studies have linked inflammatory markers with symptom severity and treatment outcomes, but the results are inconsistent, and the observed effects are generally small. A 2026 umbrella review concluded that the evidence does not yet support using inflammatory biomarkers to guide routine treatment decisions [8].
Not All Depression Is Inflammatory
Inflammation is not the cause of every case of depression. Major depressive disorder is highly heterogeneous, and symptoms may emerge from different combinations of genetic susceptibility, chronic stress, trauma, hormonal changes, sleep disruption, medical conditions, social and psychological factors, and altered signaling across multiple biological systems.
Depending on the definition and CRP threshold used, studies suggest that roughly one-quarter of people with major depressive disorder may have evidence of low-grade inflammation, while a smaller proportion show more marked CRP elevation [9]. This possible inflammatory subgroup is one reason researchers are investigating more personalized treatment approaches.
For a broader look at why depression cannot be reduced to one chemical deficiency, read The “Chemical Imbalance” Theory of Depression: What Modern Research Says.
What Factors Are Associated With Inflammatory Signaling?
Factors associated with chronic inflammatory signaling include obesity, insufficient or disrupted sleep, physical inactivity, smoking, heavy alcohol use, chronic stress, insulin resistance, chronic infections, and autoimmune or inflammatory diseases. Many of these factors are also independently associated with depression, which makes cause and effect difficult to separate.
Can Reducing Inflammation Improve Mood?
Evidence suggests that anti-inflammatory strategies may reduce depressive symptoms in some groups, but this does not establish inflammation as the main cause of depression or make anti-inflammatory treatment appropriate for everyone. Conventional depression treatments remain important, and medications or supplements should not be started or stopped without guidance from a qualified healthcare professional.
Exercise
Regular physical activity can improve depressive symptoms and may also reduce chronic inflammatory signaling over time [10,11]. Exercise can influence insulin sensitivity, sleep, stress regulation, and neuroplasticity, so its mental health effects cannot be attributed to inflammation alone.
Dietary Patterns
Dietary patterns emphasizing fruits and vegetables, whole grains, legumes, nuts, fish, and olive oil are associated with better cardiometabolic health. Randomized-trial evidence indicates that Mediterranean-style diets can lower some inflammatory markers [12]. Trials in people with depression have also reported symptom improvement, although diet should be viewed as one component of care rather than a replacement for indicated treatment.
Sleep
Sleep and inflammation influence one another. A systematic review and meta-analysis found that sleep disturbance and long sleep duration were associated with higher levels of certain inflammatory markers, while experimental sleep loss affected inflammatory signaling [13]. Supporting consistent, restorative sleep may benefit both mood and overall health. Learn more in How Your Day Shapes the Biology of Depression: Sleep, Movement, Food, and Light.
Stress Management
Psychological stress can influence nervous-system, endocrine, and immune activity. Approaches such as mindfulness, meditation, cognitive behavioral therapy, yoga, and breathing exercises may help some people manage stress and depressive symptoms. Research on their effects on inflammatory biomarkers is mixed, however, and any average biomarker changes appear to be small [14].
Omega-3 Fatty Acids
Omega-3 fatty acids, particularly formulations containing more eicosapentaenoic acid (EPA), have shown modest adjunctive antidepressant effects in some meta-analyses [15]. Anti-inflammatory and inflammation-resolving pathways are among the proposed mechanisms, but the clinical response is variable. Omega-3 supplements can interact with medications or be unsuitable for some people, so individual guidance matters.
The Future of Personalized Depression Care
Researchers are studying whether markers such as CRP, IL-6, and TNF-α could help identify people who are more likely to benefit from particular treatments. This remains an active research area rather than routine clinical practice. Current findings are too inconsistent, and their effects too small, to support using inflammatory biomarkers alone to diagnose depression or select treatment [8].
Future research may clarify whether combinations of biomarkers, symptoms, medical history, and other clinical information can identify meaningful subtypes. Any useful precision-medicine approach will need to improve outcomes beyond careful clinical assessment.
To learn why antidepressants may help even when depression is not a simple serotonin deficiency, read How Antidepressants (SSRIs) Actually Work: Beyond the “Serotonin Imbalance” Theory.
Conclusion
Research on inflammation and cytokines has expanded our understanding of depression beyond a neurotransmitter-only model. The evidence supports an association between depressive disorders and altered immune signaling at the group level, and inflammation may contribute to symptoms in a subset of people.
At the same time, inflammation does not explain every case, and a single inflammatory marker cannot currently diagnose depression or determine the best treatment. The most accurate view is a systems-level one in which the brain, immune system, metabolism, environment, and lived experience interact.
Physical activity, restorative sleep, a nutrient-rich dietary pattern, stress management, and appropriate medical care can all support mental and physical health. For people experiencing persistent depressive symptoms, these strategies are best considered alongside evaluation and evidence-based care from a qualified healthcare professional.
References
[1] A.G. Bottaccioli, M. Bologna, F. Bottaccioli. Rethinking Depression—Beyond Neurotransmitters: An Integrated Psychoneuroendocrineimmunology Framework for Depression's Pathophysiology and Tailored Treatment. International Journal of Molecular Sciences. 2025;26:2759. https://doi.org/10.3390/ijms26062759.
[2] A.H. Miller. Advancing an Inflammatory Subtype of Major Depression. American Journal of Psychiatry. 2025;182:516–524. https://doi.org/10.1176/appi.ajp.20250289.
[3] D. Furman, J. Campisi, E. Verdin, et al. Chronic inflammation in the etiology of disease across the life span. Nature Medicine. 2019;25:1822–1832. https://doi.org/10.1038/s41591-019-0675-0.
[4] A. Gędek, S. Modrzejewski, M. Materna, et al. Altered Cytokine Levels in the First Episode of Major Depression and in Antidepressant-Naïve Patients: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences. 2025;26:10362. https://doi.org/10.3390/ijms262110362.
[5] Y. Dowlati, N. Herrmann, W. Swardfager, et al. A Meta-Analysis of Cytokines in Major Depression. Biological Psychiatry. 2010;67:446–457. https://doi.org/10.1016/j.biopsych.2009.09.033.
[6] T. Yang, Z. Nie, H. Shu, et al. The Role of BDNF on Neural Plasticity in Depression. Frontiers in Cellular Neuroscience. 2020;14:82. https://doi.org/10.3389/fncel.2020.00082.
[7] E.F. Osimo, T. Pillinger, I.M. Rodriguez, et al. Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls. Brain, Behavior, and Immunity. 2020;87:901–909. https://doi.org/10.1016/j.bbi.2020.02.010.
[8] L. Baxter, N. Utulu, F. Utulu, et al. An umbrella review of inflammatory biomarkers and their relationship to treatment response in major depressive disorder. Neuroscience & Biobehavioral Reviews. 2026;188:106806. https://doi.org/10.1016/j.neubiorev.2026.106806.
[9] E.F. Osimo, E.J. Baxter, G.M. Lewis, P.B. Jones, G.M. Khandaker. Prevalence of low-grade inflammation in depression: A systematic review and meta-analysis of CRP levels. Psychological Medicine. 2019;49:1958–1970. https://doi.org/10.1017/S0033291719001454.
[10] M. Noetel, T. Sanders, D. Gallardo-Gómez, et al. Effect of exercise for depression: Systematic review and network meta-analysis of randomised controlled trials. BMJ. 2024;384:e075847. https://doi.org/10.1136/bmj-2023-075847.
[11] O. Magni, G. Arnaoutis, D. Panagiotakos. The impact of exercise on chronic systemic inflammation: A systematic review and meta-meta-analysis. Sport Sciences for Health. 2025;21:1405–1417. https://doi.org/10.1007/s11332-025-01445-3.
[12] M. Keshani, S. Rafiee, H. Heidari, et al. Mediterranean Diet Reduces Inflammation in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Nutrition Reviews. 2026;84:1776–1790. https://doi.org/10.1093/nutrit/nuaf213.
[13] M.R. Irwin, R. Olmstead, J.E. Carroll. Sleep Disturbance, Sleep Duration, and Inflammation: A Systematic Review and Meta-Analysis of Cohort Studies and Experimental Sleep Deprivation. Biological Psychiatry. 2016;80:40–52. https://doi.org/10.1016/j.biopsych.2015.05.014.
[14] L. Sanada, R. Montero-Marin, A. Barceló-Soler, et al. Effects of Mindfulness-Based Interventions on Biomarkers and Low-Grade Inflammation in Patients With Psychiatric Disorders: A Meta-Analytic Review. International Journal of Molecular Sciences. 2020;21:2484. https://doi.org/10.3390/ijms21072484.
[15] K.P. Su, P. Wang, P.J. Pae. Omega-3 polyunsaturated fatty acids for major depressive disorder. Expert Opinion on Investigational Drugs. 2013;22:1519–1534. https://doi.org/10.1517/13543784.2013.836487.
